Chromocell to Participate in the Virtual Investor Lunch Break Series

Rhea-AI Summary

Chromocell Therapeutics (NYSE American: CHRO), a leader in non-opioid pain treatment development, has announced its participation in the Virtual Investor Lunch Break Series. The event, titled 'The Chromocell Opportunity,' is scheduled for Thursday, July 18, 2024, at 12:00 PM ET.

Frank Knuettel II, serving as both CEO and CFO, will present a corporate overview and business outlook. The session will include a live Q&A segment, allowing attendees to submit questions. A live video webcast will be available on the company's website, with a replay accessible for 90 days following the event.

Live webcast with Frank Knuettel II, Chief Executive Officer and Chief Financial Officer, on Thursday, July 18th at 12:00 PM ET

FREEHOLD, N.J., July 15, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that it will present at the Virtual Investor Lunch Break: The Chromocell Opportunity event on Thursday, July 18, 2024 at 12:00 PM ET.

As part of the event, Frank Knuettel II, Chief Executive Officer and Chief Financial Officer of Chromocell, will provide a corporate overview and business outlook. In addition to the prepared remarks, interested parties will have the opportunity to submit questions live during the event. Mr. Knuettel will answer as many questions as possible in the time allowed.

A live video webcast of the event will be available on the Events page under the Investors section of the Company’s website (chromocell.com). A webcast replay will be available two hours following the live event and will be accessible for 90 days.

About Chromocell Therapeutics

Chromocell Therapeutics Corporation is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain and other associated medical conditions. The Company’s initial clinical focus is to selectively target the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic neuropathic pain and acute and chronic eye pain. The Company’s portfolio also includes pre-clinical work on other sodium channel receptor subtypes, and the Company intends to explore these and other compounds for the treatment of additional pain indications. For company updates and to learn more about Chromocell, visit www.chromocell.com or follow us on social media.

Investor Contact:

LR Advisors LLC.
Jason Assad
678-570-6791
Jason@Chromocell.com

FAQ

When is Chromocell Therapeutics (CHRO) participating in the Virtual Investor Lunch Break Series?

Chromocell Therapeutics (CHRO) is participating in the Virtual Investor Lunch Break Series on Thursday, July 18, 2024, at 12:00 PM ET.

Who will be presenting at the Chromocell (CHRO) Virtual Investor event?

Frank Knuettel II, the Chief Executive Officer and Chief Financial Officer of Chromocell, will be presenting at the Virtual Investor event.

What will be discussed during Chromocell's (CHRO) Virtual Investor Lunch Break presentation?

The presentation will include a corporate overview and business outlook for Chromocell Therapeutics, followed by a live Q&A session.

How can investors access Chromocell's (CHRO) Virtual Investor Lunch Break presentation?

Investors can access a live video webcast of the event on the Events page under the Investors section of Chromocell's website (chromocell.com).

How long will the replay of Chromocell's (CHRO) Virtual Investor presentation be available?

The webcast replay will be available for 90 days following the live event on July 18, 2024.